Lipum AB (publ) has published the interim report Q1 for the period January-March 2024. Below is a summary, a complete report (only in Swedish) is available on the company's website.
CEO Ola Sandborgh comments: “I can with pride look back to a fantastic start of a new year. We continue according to plan and will in 2024, be able to complete and report on all three parts of the phase 1 study. At the same time, we will initiate the preparations of an exciting and potentially value increasing phase 2 program.”
Financial summary January – March 2024
- Net sales: KSEK 0 (0)
- Result after financial items: KSEK -9 313 (-7 173)
- Cash and cash equivalents as of March 31: KSEK 1 473 (26 765)
Significant events during the period January – March 2024
- Lipum reports positive interim results from clinical phase 1 study showing that SOL-116 reduces plasma BSSL levels in healthy subjects.
- Lipum carries out a rights issue.
- Lipum reports first patient included in the ongoing phase 1 clinical study.
- Lipum enters an agreement with NorthX Biologics for manufacturing of SOL‑116 intended for use in phase 2 clinical studies.
Significant events after the period
- Lipum strengthens its protection of SOL-116 through a patent application for inflammation-driven cancer.
- Lipum has been granted MSEK 2.8 funding from Swelife.
- Lipum announces final outcome of the rights issue thus raises proceeds of MSEK 79.7 and receives a loan commitment of MSEK 20.
CEO Ola Sandborgh comments on the report in a live webcast on May 28 at 09:00 link.
The complete report (only in Swedish) is available at ww.lipum.se.